Do analysts recommend CTXR or NCNA?

Citius Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 629.93%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, CTXR or NCNA?

NuCana is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Pharmaceuticals N/A N/A -$37.43M -$2.13 N/A NuCana N/A N/A -$38.71M -$2.98 N/A

Is CTXR or NCNA more profitable?

Citius Pharmaceuticals' return on equity of -61.09% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets Citius Pharmaceuticals N/A -61.09% -35.36% NuCana N/A -153.61% -116.03%

Does the media favor CTXR or NCNA?

In the previous week, Citius Pharmaceuticals had 2 more articles in the media than NuCana. MarketBeat recorded 3 mentions for Citius Pharmaceuticals and 1 mentions for NuCana. Citius Pharmaceuticals' average media sentiment score of 0.34 beat NuCana's score of 0.00 indicating that Citius Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NuCana 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend DARE or NCNA?

Dare Bioscience currently has a consensus price target of $10.00, suggesting a potential upside of 627.27%. Given Dare Bioscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Dare Bioscience is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is DARE or NCNA more profitable?

Dare Bioscience's return on equity of 0.00% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% NuCana N/A -153.61% -116.03%

Does the media prefer DARE or NCNA?

In the previous week, Dare Bioscience had 2 more articles in the media than NuCana. MarketBeat recorded 3 mentions for Dare Bioscience and 1 mentions for NuCana. Dare Bioscience's average media sentiment score of 0.00 equaled NuCana'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NuCana 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CLRB or NCNA?

Cellectar Biosciences presently has a consensus price target of $11.00, suggesting a potential upside of 330.53%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Cellectar Biosciences is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, CLRB or NCNA?

NuCana is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A NuCana N/A N/A -$38.71M -$2.98 N/A

Is CLRB or NCNA more profitable?

NuCana's return on equity of -153.61% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% NuCana N/A -153.61% -116.03%

Do analysts recommend VYNE or NCNA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VYNE or NCNA more profitable?

NuCana has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets VYNE Therapeutics -4,726.21% -70.42% -63.46% NuCana N/A -153.61% -116.03%

Does the media prefer VYNE or NCNA?

In the previous week, VYNE Therapeutics and VYNE Therapeutics both had 1 articles in the media. NuCana's average media sentiment score of 0.00 beat VYNE Therapeutics' score of -0.36 indicating that NuCana is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VYNE Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NuCana 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NCNA or TVRD?

Tvardi Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 919.83%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Is NCNA or TVRD more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -153.61% -116.03% Tvardi Therapeutics N/A -64.17% -43.90%

NuCana (NCNA) Competitors

$1.45 -0.02 (-1.36%)

As of 12:23 PM Eastern

Compare

NCNA vs. CTXR, DARE, CLRB, VYNE, and TVRD

Should you buy NuCana stock or one of its competitors? MarketBeat compares NuCana with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NuCana include Citius Pharmaceuticals (CTXR), Dare Bioscience (DARE), Cellectar Biosciences (CLRB), VYNE Therapeutics (VYNE), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceuticals" industry.

How does NuCana compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and NuCana (NASDAQ:NCNA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 31.2% of NuCana shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Citius Pharmaceuticals had 2 more articles in the media than NuCana. MarketBeat recorded 3 mentions for Citius Pharmaceuticals and 1 mentions for NuCana. Citius Pharmaceuticals' average media sentiment score of 0.34 beat NuCana's score of 0.00 indicating that Citius Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NuCana	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Citius Pharmaceuticals has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, NuCana has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market.

NuCana is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A

Citius Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 629.93%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Citius Pharmaceuticals' return on equity of -61.09% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-61.09%	-35.36%
NuCana	N/A	-153.61%	-116.03%

Summary

Citius Pharmaceuticals beats NuCana on 10 of the 13 factors compared between the two stocks.

How does NuCana compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and NuCana (NASDAQ:NCNA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Dare Bioscience's return on equity of 0.00% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
NuCana	N/A	-153.61%	-116.03%

In the previous week, Dare Bioscience had 2 more articles in the media than NuCana. MarketBeat recorded 3 mentions for Dare Bioscience and 1 mentions for NuCana. Dare Bioscience's average media sentiment score of 0.00 equaled NuCana'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NuCana	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dare Bioscience has higher revenue and earnings than NuCana. Dare Bioscience is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	20.13	-$13.40M	-$0.95	N/A
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A

Dare Bioscience has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, NuCana has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market.

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 44.0% of NuCana shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by insiders. Comparatively, 31.2% of NuCana shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Dare Bioscience currently has a consensus price target of $10.00, suggesting a potential upside of 627.27%. Given Dare Bioscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Dare Bioscience is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Dare Bioscience beats NuCana on 9 of the 13 factors compared between the two stocks.

How does NuCana compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and NuCana (NASDAQ:NCNA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by insiders. Comparatively, 31.2% of NuCana shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cellectar Biosciences has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, NuCana has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market.

NuCana's return on equity of -153.61% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
NuCana	N/A	-153.61%	-116.03%

In the previous week, NuCana had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 1 mentions for NuCana and 0 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.00 equaled NuCana'saverage media sentiment score.

Company	Overall Sentiment
Cellectar Biosciences	Neutral
NuCana	Neutral

NuCana is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A

Cellectar Biosciences presently has a consensus price target of $11.00, suggesting a potential upside of 330.53%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Cellectar Biosciences is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

NuCana beats Cellectar Biosciences on 7 of the 13 factors compared between the two stocks.

How does NuCana compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and NuCana (NASDAQ:NCNA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NuCana has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
NuCana	N/A	-153.61%	-116.03%

In the previous week, VYNE Therapeutics and VYNE Therapeutics both had 1 articles in the media. NuCana's average media sentiment score of 0.00 beat VYNE Therapeutics' score of -0.36 indicating that NuCana is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NuCana	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

VYNE Therapeutics has higher revenue and earnings than NuCana. VYNE Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	33.29	-$26.48M	-$0.38	N/A
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by insiders. Comparatively, 31.2% of NuCana shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

VYNE Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the broader market. Comparatively, NuCana has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market.

Summary

VYNE Therapeutics beats NuCana on 6 of the 11 factors compared between the two stocks.

How does NuCana compare to Tvardi Therapeutics?

NuCana (NASDAQ:NCNA) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, NuCana had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 1 mentions for NuCana and 0 mentions for Tvardi Therapeutics. NuCana's average media sentiment score of 0.00 equaled Tvardi Therapeutics'average media sentiment score.

Company	Overall Sentiment
NuCana	Neutral
Tvardi Therapeutics	Neutral

Tvardi Therapeutics' return on equity of -64.17% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Tvardi Therapeutics has higher revenue and earnings than NuCana. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
Tvardi Therapeutics	$7.14M	2.32	-$18.21M	-$3.10	N/A

NuCana has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

Tvardi Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 919.83%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

44.0% of NuCana shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 31.2% of NuCana shares are held by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Tvardi Therapeutics beats NuCana on 9 of the 14 factors compared between the two stocks.

Get NuCana News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCNA vs. The Competition

Export

Metric	NuCana	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.03M	$11.91B	$7.03B	$12.96B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-0.49	788.49	269.93	24.86
Price / Sales	N/A	968.58	650.62	108.28
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	0.19	10.34	11.25	6.44
Net Income	-$38.71M	$2.77B	$3.45B	$347.39M
7 Day Performance	7.41%	2.18%	3.67%	2.69%
1 Month Performance	8.21%	-1.35%	-0.49%	-0.90%
1 Year Performance	N/A	191.22%	77.44%	23.51%

NuCana Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCNA NuCana	0.3438 of 5 stars	$1.45 -1.4%	N/A	N/A	$6.03M	N/A	N/A	30	Positive News Upcoming Earnings
CTXR Citius Pharmaceuticals	2.3851 of 5 stars	$0.64 -17.8%	$5.00 +678.8%	-44.5%	$21.44M	N/A	N/A	20	News Coverage Upcoming Earnings High Trading Volume
DARE Dare Bioscience	2.2217 of 5 stars	$1.33 -0.7%	$10.00 +651.9%	-27.1%	$20.21M	$1.03M	N/A	30	Upcoming Earnings
CLRB Cellectar Biosciences	2.1469 of 5 stars	$2.52 flat	$11.00 +336.5%	-45.7%	$20.14M	N/A	N/A	10	Upcoming Earnings
VYNE VYNE Therapeutics	0.6379 of 5 stars	$28.33 -0.8%	N/A	+58.7%	$18.98M	$570K	N/A	30	Upcoming Earnings Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCNA) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NuCana (NCNA) Competitors

NCNA vs. CTXR, DARE, CLRB, VYNE, and TVRD

How does NuCana compare to Citius Pharmaceuticals?

Summary

How does NuCana compare to Dare Bioscience?

Summary

How does NuCana compare to Cellectar Biosciences?

Summary

How does NuCana compare to VYNE Therapeutics?

Summary

How does NuCana compare to Tvardi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NuCana (NCNA) Competitors

NCNA vs. CTXR, DARE, CLRB, VYNE, and TVRD

How does NuCana compare to Citius Pharmaceuticals?

Do insiders & institutionals hold more shares of CTXR or NCNA?

Does the media favor CTXR or NCNA?

Which has more volatility and risk, CTXR or NCNA?

Which has stronger earnings & valuation, CTXR or NCNA?

Do analysts recommend CTXR or NCNA?

Is CTXR or NCNA more profitable?

Summary

How does NuCana compare to Dare Bioscience?

Is DARE or NCNA more profitable?

Does the media prefer DARE or NCNA?

Which has better earnings & valuation, DARE or NCNA?

Which has more risk and volatility, DARE or NCNA?

Do insiders and institutionals have more ownership in DARE or NCNA?

Do analysts recommend DARE or NCNA?

Summary

How does NuCana compare to Cellectar Biosciences?

Do insiders and institutionals have more ownership in CLRB or NCNA?

Which has more volatility and risk, CLRB or NCNA?

Is CLRB or NCNA more profitable?

Does the media prefer CLRB or NCNA?

Which has higher earnings & valuation, CLRB or NCNA?

Do analysts rate CLRB or NCNA?

Summary

How does NuCana compare to VYNE Therapeutics?

Do analysts recommend VYNE or NCNA?

Is VYNE or NCNA more profitable?

Does the media prefer VYNE or NCNA?

Which has higher valuation and earnings, VYNE or NCNA?

Do insiders and institutionals hold more shares of VYNE or NCNA?

Which has more volatility and risk, VYNE or NCNA?

Summary

How does NuCana compare to Tvardi Therapeutics?

Does the media refer more to NCNA or TVRD?

Is NCNA or TVRD more profitable?

Which has preferable valuation & earnings, NCNA or TVRD?

Which has more risk and volatility, NCNA or TVRD?

Do analysts recommend NCNA or TVRD?

Do insiders and institutionals have more ownership in NCNA or TVRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools